Radioactive Labeled Compound for Noninvasive EGFR Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting secondary mutations of the epidermal growth factor receptor (EGFR) in lung cancer are invasive and lack noninvasive alternatives, leading to challenges in monitoring resistance to EGFR-TKI treatments.
Innovation Solution
A radioactive labeled compound with a pyrido[3,4-d]pyrimidine skeleton is developed, allowing for noninvasive detection of secondary EGFR mutations through nuclear medicine diagnostic imaging, specifically distinguishing between L858R and T790M mutations using PET imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic tests are performed using cancer tissue collected by biopsy, then accurate detection of EGFR mutation status is achieved, but invasive procedures cause physical burden and various risks to patients
Solution Approach 1:
The patent replaces the mechanical invasive biopsy system with a non-invasive nuclear medicine imaging system. The radioactive labeled compound (1) is administered to patients and accumulates in EGFR-expressing tissues, allowing mutation status detection through external imaging without physical tissue sampling. This substitution eliminates the harmful effects of invasive procedures while maintaining diagnostic capability.
Solution Approach 2:
The patent introduces a radioactive labeled compound (1) as an intermediary substance that mediates between the detection system and the target tissue. This compound specifically binds to EGFR and carries a radioactive label, serving as a bridge that enables non-invasive detection of EGFR mutation status by translating molecular-level information into detectable radiation signals.
2Reliability
If repeated genetic tests are conducted to monitor secondary mutations during EGFR-TKI treatment, then resistance development can be detected, but repeated invasive biopsies increase patient burden and risk
Solution Approach 1:
The patent replaces repeated invasive biopsy procedures with non-invasive nuclear medicine imaging for longitudinal monitoring. The radioactive labeled compound (1) can be administered multiple times to track changes in EGFR mutation status during EGFR-TKI treatment, enabling detection of secondary mutations and resistance development without subjecting patients to repeated physical trauma and treatment interruptions.
3Loss of information
If conventional imaging methods are used for cancer diagnosis, then general tumor detection is achieved, but specific detection of EGFR mutation status and secondary mutations is not possible
Solution Approach 1:
The patent uses a radioactive labeled compound (1) as a molecular intermediary that specifically targets EGFR. This compound carries both the molecular recognition element (pyrido[3,4-d]pyrimidine core structure that binds to EGFR) and the detection element (radioactive label), enabling conventional imaging systems to visualize specific molecular information about EGFR mutation status without requiring complex new imaging infrastructure.
Solution Approach 2:
The patent changes the detection parameter from general anatomical imaging to molecular-specific functional imaging. By incorporating a radioactive label into the EGFR-targeting compound, the system transforms conventional imaging capabilities into a tool that can detect specific molecular parameters such as EGFR expression levels and mutation status, providing information that cannot be obtained through structural imaging alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the noninvasive evaluation of EGFR mutation status and treatment efficacy, facilitating the monitoring of resistance development and optimizing EGFR-TKI therapy in lung cancer patients.
Implementation Method 1
X 1 is a radioactive halogen atom
Implementation Method 2
specifically distinguishing between L858R and T790M mutations using PET imaging
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided is a radioactive labeled compound that can detect a secondary mutation of an epidermal growth factor receptor and which is a compound represented by Formula (1) described below or a pharmaceutically acceptable salt thereof. In Formula (1), L1 is an alkanediyl group having 1 to 5 carbon atoms or an alkenediyl carbonyl group having 3 to 8 carbon atoms, R1 is a radioactive halogen atom, or 5- to 7-membered monocyclic nitrogen-containing heterocycloalkyl that may have one substituent, R2 is a 6- to 8-membered aryl group or nitrogen-containing heteroaryl group with one substituent, R1 or R2 contains a radioactive halogen atom or a radioactive carbon atom (11C), and Y is -NH- or -O-.